BDFA Response to NICE Final Draft Guidance not Recommending Cerliponase Alfa for Treating Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)

What does this NICE decision mean?

The Batten Disease Family Association CIO (BDFA), is deeply disappointed with today’s final draft guidance announced by the National Institute for Health and Care Excellence (NICE) not to recommend cerliponase alfa (Brineura) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2 variant of Batten disease).

The decision means that, after 31 December 2025, only children currently receiving Brineura can continue to receive treatment. Those newly diagnosed with this deadly disease after this date will be denied access to the therapy.

Brineura is the only available treatment that targets the underlying cause of the CLN2 variant of Batten disease. It has been shown to slow the onset of disability and progression of the disease. Without this therapy, the typical lifespan of a child with the condition is just six to twelve years and results in seizures, severe disability, progressive dementia and death.

The BDFA will be appealing the draft NICE decision. Our mission is to enable those affected by Batten disease to live life to the full and to provide families with the care and support they need. By denying newly diagnosed children in the future access to this life-changing treatment, NICE’s decision will cause huge stress and uncertainty to families who are already struggling to cope with the devastating diagnosis of a child.

What is NICE’s rationale for the decision?

In its final draft guidance, NICE accepted that Brineura slows progression of the CLN2 variant of Batten disease, based on clinical evidence. But despite hearing from patient and clinical experts about the transformative nature of Brineura, NICE cited a lack of evidence about its long-term effectiveness and its cost as reasons for not recommending the treatment for newly-diagnosed children in the future.

The published final draft guidance can be accessed via the NICE website https://www.nice.org.uk/guidance/indevelopment/gid-hst10061/documents.

 

Comment from the BDFA

Liz Brownnutt, Chief Executive Officer of the BDFA, said:

“We are extremely disappointed by the NICE decision. Denying Brineura for children diagnosed in the future is not just a cost decision. It is a choice — a choice to allow preventable suffering and premature death in children who could otherwise survive longer and live better. That is a choice this country cannot and must not make. The Batten community needs full, unrestricted approval of Brineura for all current and future children with CLN2, without cut-off dates and without arbitrary conditions. We will be appealing this decision and urging NICE to correct this course. We will not step back or stand by while children are denied hope, denied treatment, and denied life.”

What are the next steps?

The BDFA will be appealing the NICE decision by the deadline of 29 August 2025.

For any enquiries, please contact Liz Brownnutt; lizbrownnutt@bdfa-uk.org.uk